Clarivate Plc (CLVT)
Pre-Market:
- PR Newswire
Clarivate Introduces Epidemiology Intelligence™ for Precision Patient Population Analysis
Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of Epidemiology Intelligence™. The new solution combines rich insights from epidemiology, incidence and prevalence database solutions. It includes U.S. claims-based population insights to empower biopharma companies to accurately gauge market size and target patient demographics with ease.
- PR Newswire
Clarivate Enhances Cortellis CMC Intelligence with Post-Approval Module to Accelerate Regulatory Success
Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of the newly enhanced Cortellis CMC Intelligence™ solution, featuring a new post-approval variations module. The module for post-approval variations covers regulatory changes across multiple countries, offering meticulously curated requirements to streamline tracking. With this update, pharmaceutical, biotech, and generics companies can effortlessly navigate the regulatory process and
- PR Newswire
Clarivate Declares Dividend on Mandatory Convertible Preferred Shares
Clarivate Plc (NYSE: CLVT; CLVT PR A) ("Clarivate"), a leading global provider of transformative intelligence, today announced that its board of directors declared a quarterly dividend of $1.3125 per share on its 5.25% Series A Mandatory Convertible Preferred Shares (the "Preferred Shares"), payable in cash on June 3, 2024 to shareholders of record at the close of business on May 15, 2024.
